Lung Cancer Trials Ask AI to find trials
RecruitingNot applicableNCT03774758
Official study title

Biomarkers for Risk Stratification in Lung Cancer

Study summary

This is a prospective observational study that will follow patients who undergo lung cancer screening at the San Francisco VA Medical Center, University of California, San Francisco (UCSF) Medical Center, and the San Francisco General Hospital. The proposed study will comprise of two primary populations to determine the ctDNA assay performance in a variety of clinical settings.

Ask AI to explain this study
Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedGuardant Health ct-DNA LUNAR assay

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Oct 14, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Not applicable

Observational

Where is it offered?3 U.S. locations

Locations may change over time.

Who runs it?University of California, San Francisco

Study sponsor

01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
University of California, San Francisco
Interventions being studied
Diagnostic Test: Guardant Health ct-DNA LUNAR assay
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Age ≥ 40 years
  • Ability to understand and provide written informed consent
  • Willingness to comply with study protocols and provide blood samples.
  • Willingness to complete 3-year clinical follow up
Reasons someone may not be able to joinExclusion criteria

Active non-cutaneous malignancy within the past 5 years as per medical record or patient report.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Zuckerberg San Francisco General Hospital and Trauma CenterSan Francisco, California
  • San Francisco VA Medical CenterSan Francisco, California
  • University of California, San FranciscoSan Francisco, California

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 14, 2026. Always confirm current availability with the study team.

View original record ↗